Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Tecan to participate in Morgan Stanley Healthcare Conference in New York
Tecan will participate on 14 September 2026 in the 24th annual Morgan Stanley Healthcare Conference in New York and will be represented in a fireside chat. Participants are CEO Monica Manotas, CFO Camila Japur and Martin BrÀndle (SVP Corporate Communications & IR); a webcast will be streamed live on the investor overview at www.tecan.com and will be available for 120 days. » More on finanzen.net
Tecan falls after H1 figures and cautious outlook
Tecan reported H1 2026 revenue of 427.5 million CHF and adjusted EBITDA of 64.5 million CHF (margin 15.1%), but showed weaker reported revenue, a sharply reduced operating cash flow of 17 million CHF and margin pressure. The share fell about 9% to $183.90 as investors reacted particularly to the decline in gross margins and continued transformation spending. Management kept the full-year guidance unchanged and expects low single-digit revenue growth and an adjusted EBITDA margin of 15.5â16.5%, now targeting the top end of the range. » More on de.investing.com
Tecan announces conference call to present half-year results on 11 August
Tecan will explain the financial results for the first half of 2026 on Tuesday, 11 August 2026 at 09:00 CET in an English-language conference call; the press release will be published the same morning at 07:00 CET. The presentation will be available via telephone dial-in or webcast with synchronized slides; dial-in details will be published in advance. The full half-year report 2026 will be available from 11 August in the Investor Relations section of the company website. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 463.16m | - |
| Gross profit | 157.02m | - |
| Net profit | 13.29m | - |
| EBITDA | 50.64m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ2.61bn |
Number of shares | 12.53m |
52-week high/low | âŹ435.68 - âŹ205.62 |
Dividend yield | 1.58% |
Dividends TTM | âŹ3.27 |
Beta | 1.08 |
P/E ratio | -21.51 |
PEG ratio | 0.08 |
P/B ratio | 2.18 |
P/S ratio | 2.86 |
Company profile
Die Tecan Group AG bietet Laborinstrumente und -lösungen fĂŒr Pharma- und Biotechnologieunternehmen, universitĂ€re Forschungsabteilungen sowie forensische und diagnostische Labors an. Das Unternehmen ist in den Segmenten Life Sciences Business und Partnering Business tĂ€tig. Das Unternehmen bietet Liquid Handling und Automation, Mikroplatten-Reader und Washers, Verbrauchsmaterialien, NGS-Reagenzien, Immunoassays und Mikrokörper sowie Software; Tecan Laberwax, eine Automationslösung; Resolvex, eine intelligente Probenvorbereitungslösung fĂŒr den Einsatz in der Genomik, der synthetischen Biologie, der Arzneimittelforschung, der analytischen Chemie, der Zellbiologie, der Proteinforschung, in angewandten MĂ€rkten und ELISA-Lösungen. DarĂŒber hinaus entwickelt und produziert das Unternehmen LaborgerĂ€te mit wesentlichen Komponenten wie PrĂ€zisionspumpen, Ventilen, Roboterarmen und Entwicklersoftware fĂŒr die Life-Science-Forschung, die Diagnostik und verschiedene andere Industriezweige; Synergence, eine plattformbasierte Automatisierungslösung, sowie die Instrumente Freedom EVO und Fluent. Das Unternehmen ist in der Schweiz und anderen europĂ€ischen LĂ€ndern, in Nordamerika, Asien und international tĂ€tig. Die Tecan Group AG wurde 1980 gegrĂŒndet und hat ihren Hauptsitz in MĂ€nnedorf, Schweiz.
| Name | Tecan N |
| CEO | Monica Manotas |
| Headquarters | MĂ€nnedorf,
zh Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| IPO | 10/04/1995 |
| Employees | 3,244 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
SIX | TECN.SW |
London Stock Exchange | 0QLN.L |
Pnk | TCHBF |
London | 0QLN.L |
MĂŒnchen | TEN.MU |